{
  "id": 1570312,
  "title": "Amylyx stock rises on Phase 3 trial results date",
  "url": "https://urgent.news/2026/08/17/amylyx-stock-rises-on-phase-3-trial-results-date",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T21:45:59.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/amylyx-stock-rises-on-phase-3-trial-results-date-93CH-4864032"
  },
  "original_language": "en",
  "account": null,
  "summary": "Amylyx Pharmaceuticals Inc (AMLX) shares experienced a 14.5% increase in after-hours trading following the company's announcement that it will release topline results from its Phase 3 LUCIDITY Clinical Trial of avexitide in post-bariatric hypoglycemia on August 18. Mizuho analyst Graig Suvannavejh raised the price target on Amylyx to $30.00 from $24.00, maintaining an Outperform rating, as the analyst believes the new price target implies 39% upside potential and estimates a potential incremental $10-15 move higher from current levels on a positive Phase 3 data outcome.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}